Previous 10 | Next 10 |
home / stock / aplif / aplif news
Spartan Bioscience Board Chair Brings Broad Healthcare Experience to Appili’s Leadership Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious ...
Appili Therapeutics ([[APLIF]] -2.8%) announced that its Phase 3 PRESECO (PREventing SEvere COvid-19) clinical trial is actively recruiting participants in 12 out of 20 planned sites in the United States.Appili said it will prioritize resources to accelerate recruitment a...
12 sites in the United States are actively recruiting for the double-blind placebo-controlled study in mild-to-moderate patients with COVID-19 The Company is prioritizing resources on the pivotal study and expects to provide interim data readout by late March 202 1 A...
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will participate in HC Wainwright’s ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy...
Citing government sources, Kyodo News reports that Japanese health authorities have found it difficult to conclude the effectiveness of the anti-viral drug, Avigan, developed by Fujifilm Toyama Chemical Co., a unit of Fujifilm Holdings (FUJIF).The findings by the Pharmaceuticals and Medical D...
Dosing is underway in a Phase 3 clinical trial, PRESECO, evaluating Appili Therapeutics' (APLIF) Avigen tablets (favipiravir) for the treatment of COVID-19 patients with mild-to-moderate symptoms. The goal is to alleviate the symptoms and prevent disease progression.Enrollment target is ~826 ...
Randomized, double-blind, placebo-controlled study expected to enroll more than 800 outpatients with confirmed mild-to-moderate COVID-19 infections Appili’s broad COVID-19 clinical program focuses on the use of oral antivirals as an early intervention against the corona...
Company signs agreement with CRO and files Phase 3 clinical trial protocol with U.S. FDA in advance of anticipated study initiation in the U.S. Double-blind, randomized, placebo-controlled study will include approximately 1,156 participants in the U.S. and Canada; Appili expec...
Appili Therapeutics (APLIF): F1H GAAP EPS of -$0.09.Cash and short-term investments of $22.9M.Press Release For further details see: Appili Therapeutics reports F1H results
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...